TITLE

Cervical cancer vaccine may come soon to Canada

AUTHOR(S)
Priest, Alicia
PUB. DATE
August 2006
SOURCE
CMAJ: Canadian Medical Association Journal;8/1/2006, Vol. 175 Issue 3, p235
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Offers information on Gardasil, a quadrivalent human papillomavirus, recombinant vaccine manufactured by Merck Frosst against cervical cancer. Physiological mechanism of Gardasil; Price of the vaccine; Clinical information on human papillomavirus.
ACCESSION #
21678160

 

Related Articles

  • HPV vaccine: One, two, or three doses for cervical cancer prevention? Mishra, Gauravi A.; Pimple, Sharmila A.; Shastri, Surendra S. // Indian Journal of Medical & Paediatric Oncology;Oct-Dec2015, Vol. 36 Issue 4, p201 

    The authors reflect on the availability of human papilloma virus (HPV) vaccines for preventing cervical cancers. Topics discussed include the prevalence of the disease, the efficacy of HPV vaccination as a primary prevention tool, and the outcome of the vaccine's three-dose schedule. Also...

  • HPV and Cervical Cancer. Leaver, Dennis; Labonte, Geri // Radiation Therapist;Spring2010, Vol. 19 Issue 1, p27 

    Human papillomaviruses (HPVs) are estimated to cause a half million cases of cervical cancer worldwide each year. This article reviews the connection between HPVs and cervical cancer, discusses the HPV vaccine and provides an overview of cervical cancer symptoms, staging and treatment. Case...

  • Skin Vaccination against Cervical Cancer Associated Human Papillomavirus with a Novel Micro-Projection Array in a Mouse Model. Corbett, Holly J.; Fernando, Germain J. P.; Xianfeng Chen; Frazer, Ian H.; Kendall, Mark A. F. // PLoS ONE;2010, Vol. 5 Issue 10, p1 

    Background: Better delivery systems are needed for routinely used vaccines, to improve vaccine uptake. Many vaccines contain alum or alum based adjuvants. Here we investigate a novel dry-coated densely-packed micro-projection array skin patch (Nanopatchâ„¢) as an alternate delivery system to...

  • Cervical Cancer: commercial opportunities likely to remain despite preventative potential.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p40 

    Discusses commercial opportunities in the area of cervical cancer treatment. Identification of human papillomavirus infection as the main cause of cervical cancer; Initiation of public health programs for cervical cancer to facilitate early diagnosis and treatment of the condition; Mass...

  • About this issue ... Dreyer, Greta // Southern African Journal of Gynaecological Oncology;2009, Vol. 1 Issue 2, p51 

    An introduction to the journal is presented in which the editor discusses an article on unique southern African aspects of radiation treatment for invasive cervical cancer by Dr. Hannah Simonds, a summary of the policy document of the South African HPV Advisory Board for the use of the newly...

  • Cervarix PI updated.  // Australian Journal of Pharmacy;Aug2011, Vol. 92 Issue 1095, p48 

    The article offers information on the product information (PI) of the Cervarix human papillomavirus (HPV) vaccine, which was shown as highly effective against cervical pre-cancerous lesions caused by HPV types 16 and 18.

  • The known unknowns of HPV natural history. Gravitt, Patti E. // Journal of Clinical Investigation;Dec2011, Vol. 121 Issue 12, p4593 

    The discovery that certain high-risk strains of human papillomavirus (HR-HPV) cause nearly 100% of invasive cervical cancer has spurred a revolution in cervical cancer prevention by promoting the development of viral vaccines. Although the efficacy of these vaccines has already been...

  • Merck & Co: Gardasil shows promise in older women.  // PharmaWatch: Monthly Review;Jul2009, Vol. 8 Issue 7, p13 

    The article highlights a study which showed the beneficial effect of Merck & Co. Inc.'s cervical cancer vaccine Gardasil on women aged 24 to 45. It was found that Gardasil protects against infection with human papillomavirus (HPV) types 6, 11, 16 and 18. It is noted that the drug tops in sales...

  • Gardasil Again Denied Approval for Women 27-45.  // Clinical Infectious Diseases;3/1/2009, Vol. 48 Issue 5, piv 

    The article reports on the approval for the use of Merck & Co. Inc.'s Gardasil cervical cancer vaccine by women aged 27-45. It is stated that Gardasil's efficacy drops once females have been exposed to human papilloma virus (HPV). However, analyst Tim Anderson mentions that Merck could have...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics